HCWB — HCW Biologics Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1828673 ·
Last close
$2.62
Market Cap
$17.64M
52W High
$3.99
52W Low
$0.25
ADV30
25,299,469
Next earnings
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 6,543,001 6,531,930 3,250,122 3,472,480 27,342,213 1,228,879 21,579,779
Dec 2025 27,010 5,401 -2,947,409 719,232 24,520,013 1,952,464 21,755,244
Sep 2025 15,606 3,121 -3,276,624 -4,554,336 25,445,540 1,096,909 27,552,737
Jun 2025 6,550 1,310 -3,361,829 -1,927,730 28,909,636 2,438,962 28,961,608

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,391,617
Investing CF
$0
Financing CF
$10,669,509
CapEx
$-150,475
Dividends Paid
Buybacks
EPS Diluted TTM
$-5.94
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-108,515,846
Inventory
Receivables
$32,175
ST Investments
EBIT TTM
$-6,730,753
Pretax Income TTM
$-7,959,709
Interest Exp TTM
$1,228,956
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,592,168
EBITDA
$-7,696,189
Free Cash Flow
$-11,422,740
Enterprise Value
$24,809,876
Total Cash
$1,228,879
Total Debt
$6,577,194
Shares Out
6,734,104
Trailing EPS
$-8.29
Book Value
$0.84
ROE
ROA
-19.7%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 54,232 -11,257,288 -7,959,709 24,520,013 21,755,244 -13,391,617
Dec 2024 2,566,792 -27,629,216 -30,023,814 30,236,578 37,006,750 -14,227,428
Dec 2023 2,841,794 -25,717,160 -24,994,277 28,513,660 15,051,943 -22,514,121
Dec 2022 6,722,090 -15,078,778 -14,900,703 46,809,155 9,380,649 -10,386,110
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.55

Peers — same industry

TickerNameMarket CapLastDaily %
APUS Apimeds Pharmaceuticals US, Inc. $17.86M $1.42
XCUR EXICURE, INC. $17.04M $2.67
NCEL NewcelX Ltd. $16.96M $3.15
LPCN Lipocine Inc. $18.63M $2.26
MDCX Medicus Pharma Ltd. $16.54M $0.29

News headlines (Yahoo Finance, 1h cache)

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
2026-05-22 20:02 · Yahoo
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
2026-05-21 13:53 · Yahoo
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
2026-05-18 14:35 · Yahoo
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
2026-05-14 20:25 · Yahoo
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
2026-05-14 11:30 · Yahoo
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
2026-04-30 20:20 · Yahoo
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
2026-04-27 11:30 · Yahoo
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
2026-03-31 21:05 · Yahoo
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
2026-03-17 11:50 · Yahoo
BC-Most Active Stocks
2026-03-16 14:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.